ALHC · Alignment Healthcare

The thesis

Alignment Healthcare is more likely to lag the S&P 500 over the next three months. The company cut its 2026 profit outlook on 29 October 2026, and the fourth-quarter report, expected around February 2027, shows whether medical costs are turning.

Full-year adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, as the company defines it) is now guided to at least $100 million, down from $145–163 million. The guidance implies a fourth-quarter adjusted EBITDA loss of at least $28 million, per the company's 8-K. The January membership count that follows open enrollment, which ends 7 December 2026, is the other near-term evidence.

The third-quarter report itself was mixed. Revenue was $1,358.3 million, up 36.7% from a year earlier, and adjusted EBITDA of $21.8 million landed inside the $20–30 million guided range. GAAP net loss was $8.1 million, against net income of $3.7 million a year earlier.

The shares closed at $7.50 on 12 November 2026, 70.1% below the 52-week intraday high of $25.12 on 7 July 2026, with a three-month change of −46.3%. The price already reflects the guidance cut: JPMorgan, Barclays, TD Cowen and KeyBanc lowered targets or ratings between 30 October 2026 and 3 November 2026, and the shares have held between $7.27 and $7.69 over the last five sessions.

Bullish and bearish views on Alignment Healthcare, Inc.

The bull case on Alignment Healthcare, Inc. (ALHC), in brief: revenue and membership keep growing. The bear case: full-year profit guidance fell sharply.

Bull case

• Revenue and membership keep growing. Third-quarter revenue of $1,358.3 million beat the $1.313 billion estimate cited by Benzinga, and membership reached about 301,200, up 31.2% (company 8-K, 29 October 2026). Full-year membership guidance is at least 305,000.
• Guidance is framed as a floor. CEO John Kao said on 29 October 2026 that "medical trends ran higher than expected" and that revised guidance "does not assume any benefit from the actions underway." Each guided figure is stated as "at least."
• Balance sheet funds the shortfall. The 8-K shows $727.7 million of cash and cash equivalents at 30 September 2026. An earnings review on finsee.ai put funded leverage at 2.4 times trailing 12-month adjusted EBITDA.
• Some analysts keep positive ratings. JPMorgan kept Overweight with an $8 target on 30 October 2026, and TD Cowen kept Buy with a $10 target on 2 November 2026. Both targets sit above the $7.50 close of 12 November 2026.
• Near-term star-rating revenue effect is nil. The company said on 9 October 2026 it expects no revenue impact in 2026 or 2027 from the California contract's drop to 3.5 stars, per TIKR, and plans an appeal.

Bear case

• Full-year profit guidance fell sharply. The new floor of $100 million compares with analyst estimates near $147.8 million, per finsee.ai coverage of the report. Adjusted gross profit guidance fell to at least $575 million from $630–650 million.
• Fourth quarter turns to a loss. The 8-K guides fourth-quarter adjusted EBITDA to at least a $28 million loss, with revenue of at least $1,316 million against a $1.335 billion analyst estimate cited by Benzinga. The finsee.ai review states the implied adjusted medical benefit ratio (the share of premiums spent on care) is 92.1%.
• Costs are rising faster than premiums. The third-quarter adjusted medical benefit ratio was 89.5%, about 240 basis points above a year earlier. The 8-K cites Part D seasonality, clinical-investment timing, catastrophic and skilled-nursing costs and "elevated appeals and disputes."
• The star-rating loss hits the core contract. CMS's 2027 ratings cut contract H3815, which serves about 75% of health plan members, to 3.5 stars from 4.0. Quality bonuses require 4 stars, and the 2028 payment effect is not yet quantified (TIKR, 9 October 2026).
• The accounting allegation is unresolved. Modern Healthcare reported on 8 July 2026 a former executive's complaint alleging manipulated finances. Company news since then shows no resolution.
• Insiders have sold through the decline. SEC Form 4 filings show Kao sold 557,870 shares at an average $12.77 on 10 September to 11 September 2026 under a Rule 10b5-1 plan, and Joseph Konowiecki, EVP Corporate Affairs and director, sold 4,930 shares at $7.20 on 10 November 2026.

Price setup

The shares closed at $7.50 on 12 November 2026, after $7.69 on 11 November 2026, $7.67 on 10 November 2026 and $7.27 on 9 November 2026. The 52-week closing low is $7.00, set on 2 November 2026. The close was $8.05 on 27 October 2026, the last session before the report.

The 50-day moving average is $8.79 and the 200-day moving average is $16.12, both as of 12 November 2026. The shares sit below both, and the 200-day average sits more than twice the last close, which shows how much of the July–September price has been lost.

Analyst targets cited after the report cluster at $8–$10 (JPMorgan $8, Barclays $9, TD Cowen $10). No earnings date falls inside the next 30 days, so the next scheduled company evidence is the January membership count and the fourth-quarter report.

Catalysts ahead

• 7 December 2026: Medicare annual enrollment period ends (opened 15 October 2026). Closes the window for 2027 membership; the result appears in the first-quarter 2027 report.
• ~15 February 2027 (est.): Fourth-quarter 2026 results and 2027 guidance. Tests the guided adjusted EBITDA loss of at least $28 million and shows whether cost actions are working.

What would change the view

A daily close above $9.30, which would recover most of the post-guidance drop and show the shares leading the S&P 500. Fourth-quarter adjusted EBITDA better than the guided loss of at least $28 million would also show the call wrong.

What it trades with

Alignment trades with other Medicare Advantage insurers on federal rate and star-rating news. TIKR reported on 9 October 2026 that Humana rose on the day Alignment fell, so relative star-ratings outcomes can move the shares in opposite directions. Company-specific cost and accounting items have driven the shares since July.